Strengthening First-in-Class Drug Discovery
First written in FY2017. 7 of 9 entries say "Restated". Latest entry: FY2022-Q3.
The whole theme swung hardest in 2019: 1 of 10 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2022-Q3RestatedAnnual report
「We actively explored and considered the introduction of external drug discovery programs and developed initiatives aimed at first-in-class drug discovery.」
The company continues to consider exploring and introducing external drug-discovery themes and pursuing activities aimed at first-in-class drug discovery. - FY2022-Q2RestatedAnnual report
「We actively explored and considered the introduction of external drug discovery programs and developed initiatives aimed at first-in-class drug discovery.」
The company continues to consider exploring and introducing external drug-discovery themes and pursuing activities aimed at first-in-class drug discovery. - FY2022-Q1SoftenedAnnual report
「We actively explored and considered the introduction of external drug discovery programs and developed initiatives aimed at first-in-class drug discovery.」
Regarding the exploration and introduction of external themes for first-in-class drug discovery, the disclosure has shifted from describing execution to describing consideration. - FY2021-Q2RestatedAnnual report
「The company is also actively exploring and introducing external drug-discovery themes and pursuing activities toward first-in-class drug discovery.」
The company continues to pursue first-in-class drug discovery through the exploration and introduction of external drug-discovery themes. - FY2020-Q1RestatedAnnual report
「The company is also pursuing activities toward first-in-class drug discovery by actively exploring and introducing external drug-discovery themes.」
The company continues to pursue first-in-class drug discovery through the exploration and introduction of external drug-discovery themes. - FY2019RestatedAnnual report
「The company pursued activities toward first-in-class drug discovery by actively exploring and introducing external drug-discovery themes.」
The company continues its policy of pursuing first-in-class drug discovery, including the exploration and introduction of external drug-discovery themes. - FY2019-Q3RestatedAnnual report
「The company will advance the selection and concentration of drug-discovery themes, pursue multilayered program development, and actively explore and introduce external drug-discovery themes, thereby making steady progress toward first-in-class drug discovery.」
The company continues its policy of pursuing first-in-class drug discovery through the selection and concentration of drug-discovery themes, multilayered development, and the exploration and introduction of external drug-discovery themes. - FY2018RestatedAnnual report
「The company will continue to make steady progress toward first-in-class drug discovery.」
The company continues to prioritize first-in-class drug discovery. - FY2017First statedAnnual report
「Strengthening drug discovery capabilities: initiatives aimed at first-in-class drug discovery」
Initiatives aimed at first-in-class drug discovery are explicitly identified as a priority strategy.